1. Oparil S, Haber E. The renin-angiotensin system. N Engl J Med 1974; 291: 384-401

2. Campbell DJ, Kladis A, Dunca AM. Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 1993; 22: 513-522

3. Campbell DJ. Metabolism of prorenin, renin, angiotensinogen, and the angiotensins by tissues. In: Robertson JIS and Nicholls MG eds. The renin angiotensin system. London: Gower Medical Publishing,1993: 23.1-23.23

4. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 438-449

5. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-54

6. Murakami M, Matsuda H, Hayashi K, Kubota E, Saruta T. Effects of angiotensin II generated by an ACE-independant pathway on renal hemodynamics. J Am Soc Nephrol 1996; 7: 1585 (abs)

7. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992; 19: 692-696

8. Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 1992; 19 (Suppl. II): 56-61

9. Pörsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: Implications for a novel angiotensin receptor. Br J Pharmacol 1994; 111: 652-654

10. DelliPizzi A, Hilchey SD, Bell-Quilley CP. Natriuretic action of angiotensin(1-7). Br J Pharmacol 1994; 111: 1-3

11. de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25: 924-927

12. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251

13. Burns KD, Homma T, Harris RC. The intrarenal renin-angiotensin system. Semin Nephrol 1993; 13: 13-30

14. Chansel D, Czekalski S, Pham P, Ardaillou R. Characterization of angiotensin II receptor subtypes in human glomeruli and mesangial cells. Am J Physiol 1992; 262: F432-F441

15. Sechi LA, Grady EF, Griffin CA, Kalinyak JE, Schambelan M. Distribution of angiotensin II receptor subtypes in rats and human kidney. Am J Physiol 1992; 262: F236-F240

16. Edwards RM, Aiyar N. Angiotensin II receptor subtypes in the kidney. J Am Soc Nephrol 1993; 3: 1643-1652

17. Chan DP, Sandok EK, Aarhus LL, Heublin DM, Burnett JC. Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens 1992; 5: 354-360

18. Loutzenhiser R, Epstein M, Hayashi K, Takenaka T, Forster H. Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: Studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 1991; 4 (Suppl II): 309S-314S

19. Chansel D, Vandermeersch S, Pham P, Ardaillou R. Characterization of [3H]losartan receptor in isolated rat glomeruli. Eur J Pharmacol Mol Pharmacol 1993; 247: 193-198

20. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993; 3: 1531-1540

21. Douglas JG, Romero M, Hopfer U. Signaling mechanisms coupled to the angiotensin receptor of proximal tubular epithelium. Kidney Int 1990; 38 (Suppl. 30): S43-S47

22. Xie MH, Liu FY, Wong PC, Timmermans-PBMWM, Cogan MG. Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist. Kidney Int 1990; 38: 473-479

23. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche T. Renal effects of angiotensin II-receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996; 90: 205-213

24. Edwards RM, Trizna W, Stack EJ, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 1996; 276: 125-9

25. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-ß expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-3437

26. Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464-74

27. Tanaka R, Sugihara K, Tatematsu A, Fogo A. Internephron heterogenity of growth factors and sclerosis-Modulation of platelet-derived growth factor by angiotensin II. Kidney Int 1995; 47: 131-139

28. Tufro-McReddie A, Romano LM, Harris JM, Ferder L, Gomez RA. Angiotensin II regulates nephrogenesis and renal vascular development. Am J Physiol 1995; 269: F110-5

29. Péchère-Bertschi A, Decosterd L, Biollaz J, et al. Renal hemodynamic effect of the angiotensin II antagonist irbesartan versus those of the ACE inhibitor enalapril in hypertensive patients. J Am Soc Nephrol 1996; 7: 1554 (abs)

30. Martinez F, Schmitt F, Savoiu C, et al. Effect of SR 47436(BMS 186295) on renal hemodynamics and on glomerular permselectivity in healthy humans. J Am Soc Nephrol 1994; 5: 607 (abs)

31. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-550

32. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-1351

33. Sweet CS, Rucinska EJ. Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J 1994; 15 (Suppl. D): 139-144

34. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771

35. Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40-49

36. Hutchison FN, Cui X, Webster S. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 1995; 6: 1216-1222

37. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 45: 537-43

38. Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867

39. Williams JD, Coles GA. Proteinuria-A direct cause of renal morbidity? Kidney Int 1994; 45: 443-450

40. Gansevoort RT, De Zeeuw D, De Jong PE. Long-term benefits of the antiproteinuric effect of angiotensin- converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993; 22: 202-206